ECE2022 Rapid Communications Rapid Communications 4: Pituitary and Neuroendocrinology 1 (8 abstracts)
Impaired insulin secretion without changes in insulin sensitivity explains hyperglycemia in patients with acromegaly treated by pasireotide LAR
Peter Wolf 1 , Alexandre Dormoy 2 , Luigi Maione 2 , Sylvie Salenave 2 , Jacques Young 2 , Peter Kamenicky 2 & Philippe Chanson 2
1Medical University of Vienna, Internal Medicine III, Division of Endocrinology and Metabolism; 2Université Paris-Saclay, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bicetre, France
Background: Pasireotide is a second line treatment for acromegaly. Besides the growth hormone (GH) lowering efficacy, clinical use is limited by side effects on glycemic control. The aim of this study was to evaluate longitudinal changes in beta-cell function and insulin sensitivity induced by pasireotide therapy in patients with acromegaly.
Methods: We performed a retrospective study in 33 patients. Efficacy (GH and IGF-I concentrations; tumor size) and effects on glycemic control were analyzed in all patients. In 14 patients longitudinal data on oral glucose tolerance tests were available before, shortly (mean±SD: 6.1±3.8 months) and on long term (mean±SD: 24.4±11.1 months) after initiation of pasireotide therapy. Insulin secretion (Insulinogenic index; Disposition index) and insulin sensitivity were calculated by validated indices.
Results: Hyperglycemia induced by pasireotide was mediated by impaired insulin secretion, which occurred shortly after initiation of treatment and then remained stable on long term (median (min; max): Insulinogenic index: 80 (12; 542) vs 16 (6.4; 101) vs 25 (3.7; 396) pmol/mmol, respectively; P=0.028; Disposition index 1.45 (0.42; 4.88) vs 0.53 0.17; 2.63) vs 0.60 (0.22; 1.71), respectively; P=0.024). No significant changes in insulin sensitivity were observed, despite a marked reduction of GH/IGF-I concentrations. Older age and a worse glycemic control at baseline were the strongest predictors for hyperglycemia and the need for an antidiabetic treatment.
Discussion: Worsening of glycemic control during pasireotide therapy is caused by an impaired insulin secretion, whereas insulin sensitivity is not affected. These findings might be important for the choice of the anti-diabetic treatment for pasireotide induced hyperglycemia.
Volume 81
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more